Skip to main content
SpringerLink
Log in

Oral glycoprotein IIb/IIIa antagonists in coronary artery disease

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Despite the efficacy of intravenous glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention and those presenting with acute coronary syndromes, the application of oral glycoprotein IIb/IIIa inhibition to the chronic management of coronary artery disease has not met with the same success. To explain these results, factors related to dosing, and inadequate inhibition or activation of platelet pro-coagulant activity have been recently suggested. However, although the disparity between intravenous and oral glycoprotein IIb/IIIa experience remains largely enigmatic, the discordant effect on ischemic endpoints observed within the phase III oral glycoprotein IIb/IIIa inhibitor trials potentially implicates a mechanism unrelated to platelet function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Trip MD, Cats VM, van Capelle FJ, Vreeken J: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990, 322:1549–1554.

    Article  PubMed  CAS  Google Scholar 

  2. Ault KA, Cannon CP, Mitchell J, et al.: Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999, 33:634–639.

    Article  PubMed  CAS  Google Scholar 

  3. Bhatt DL, Hirsch AT, Ringleb PA, et al.: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J 2000, 140:67–73.

    Article  PubMed  CAS  Google Scholar 

  4. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998, 338:1498–1505.

    Article  Google Scholar 

  5. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998, 338:1488–1497.

    Article  Google Scholar 

  6. The PURSUIT Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998, 339:436–443.

    Article  Google Scholar 

  7. Topol EJ, Ferguson JJ, Weisman HF, et al.: Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997, 278:479–484.

    Article  PubMed  CAS  Google Scholar 

  8. Lincoff AM, Califf RM, Moliterno DJ, et al.: Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999, 341:319–327.

    Article  PubMed  CAS  Google Scholar 

  9. Bhatt DL, Marso SP, Lincoff AM, et al.: Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000, 35:922–928.

    Article  PubMed  CAS  Google Scholar 

  10. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers. Lancet 1999, 353:227–231. Provides an excellent review of glycoprotein IIb/IIIa receptor biology.

    Article  PubMed  CAS  Google Scholar 

  11. Wagner CL, Mascelli MA, Neblock DS, et al.: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996, 88:907–914.

    PubMed  CAS  Google Scholar 

  12. Coller BS: Current concepts of thrombosis. J Invasive Cardiol 1994, 6:277–284.

    PubMed  CAS  Google Scholar 

  13. Byzova TV, Plow EF: Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin. J Cell Biol 1998, 143:2081–2092.

    Article  PubMed  CAS  Google Scholar 

  14. Cierniewski CS, Byzova T, Papierak M, et al.: Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses. J Biol Chem 1999, 274:16923–16932.

    Article  PubMed  CAS  Google Scholar 

  15. Rybak ME, Renzulli LA: Ligand inhibition of the platelet glycoprotein IIb-IIIa complex function as a calcium channel in liposomes. J Biol Chem 1989, 264:14617–14620.

    PubMed  CAS  Google Scholar 

  16. Du XP, Plow EF, Frelinger ALd, et al.: Ligands “activate” integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991, 65:409–416.

    Article  PubMed  CAS  Google Scholar 

  17. Gawaz M, Ruf A, Neumann FJ, et al.: Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998, 80:994–1001.

    PubMed  CAS  Google Scholar 

  18. The EPIC Investigation: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994, 330:956–961.

    Article  Google Scholar 

  19. Kereiakes DJ, Kleiman N, Ferguson JJ, et al.: Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997, 96:1117–11121.

    PubMed  CAS  Google Scholar 

  20. Kereiakes DJ, Runyon JP, Kleiman NS, et al.: Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation 1996, 94:906–910.

    PubMed  CAS  Google Scholar 

  21. Kereiakes DJ, Kleiman NS, Ferguson JJ, et al.: Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation 1998, 98:1268–1278.

    PubMed  CAS  Google Scholar 

  22. Cannon CP, McCabe CH, Borzak S, et al.: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation 1998, 97:340–349.

    PubMed  CAS  Google Scholar 

  23. Harrington RA, Armstrong PW, Graffagnino C, et al.: Dosefinding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation 2000, 102:728–735.

    PubMed  CAS  Google Scholar 

  24. O’Neill WW, Serruys P, Knudtson M, et al.: Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000, 342:1316–1324. Large scale clinical trial of xemilofiban.

    Article  PubMed  CAS  Google Scholar 

  25. Cannon CP, McCabe CH, Wilcox RG, et al.: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000, 102:149–156. Large scale clinical trial of orbofiban.

    PubMed  CAS  Google Scholar 

  26. The SYMPHONY Investigators: Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000, 355:337–345. Large scale clinical trial of sibrafiban.

    Article  Google Scholar 

  27. Newby K: 2nd Sibrafiban vs. aspirin to Yield Maximum Protection from Ischemic heart events Post acute coronary syndromes Study. Presented at the 49th Scientific Sessions of American College of Cardiology Meeting. Anaheim, CA: March 12–15, 2000. Large scale clinical trial of sibrafiban.

  28. Chew D, Bhatt D, Sapp S, Topol E: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a pooled analysis of the large scale oral glycoprotein IIb/IIIa trials. Circulation 2000, in press. Pooled analysis of the phase III clinical trials highlighting the disparity between mortality increases and other ischemic endpoints with the oral glycoprotein IIb/IIIa antagonists.

  29. Ferguson J, Deedwania P, Kereiakes D, et al.: Sustained platelet GP IIb/IIIa blockade with oral orbofiban: Interim pharmacodynamic results of the SOAR study. J Am Coll Cardiol 1998, 31:185A.

    Article  Google Scholar 

  30. Newby LK: Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events postacute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. Am Heart J 1999, 138:210–218.

    Article  PubMed  CAS  Google Scholar 

  31. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81–106.

    Google Scholar 

  32. Heeschen C, Hamm CW: Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists. Lancet 2000, 355:330–331.

    Article  PubMed  CAS  Google Scholar 

  33. Steinhubl S, Talley D, Kereiakes D, et al.: A prospective multicentre study to determine the optimal level of platelet inhibition with GP IIb/IIIa inhibitors in patients undergoing coronary interventin-the GOLD study. J Am Coll Cardiol 2000, 35:44A.

    Google Scholar 

  34. Impact II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of perculaneous coronary intervention: IMPACT II. Integrilin to minimise platelet aggregation and coronary Thrombosis-II. Lancet 1997, 349:1422–1428.

    Article  Google Scholar 

  35. Chew D, Moliterno D: Critical Appraisal of Glycoprotein IIb/ IIIa Inhibition. J Am Coll Cardiol 2000, in press. A discussion of the mechanisms that may compromise glycoprotein IIb/IIIa inhibition.

  36. Coller BS, Lang D, Scudder LE: Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997, 95:860–867.

    PubMed  CAS  Google Scholar 

  37. Holmes M, Sobel BE, Cannon CP, DJ S: Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome. An OPUS-TIMI 16 substudy. Am J Cardiol 2000, 85:491–493.

    Article  PubMed  CAS  Google Scholar 

  38. Peter K, Schwarz M, Ylanne J, et al.: Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors Blood 1998, 92:3240–3249.

    PubMed  CAS  Google Scholar 

  39. Coulter S, Cannon C, Cooper R, et al.: Thrombocytopenia, bleeding and thrombotic events with oral glycoprotein IIb/ IIIa inhibition. Results from OPUS TIMI 16. J Am Coll Cardiol 2000, 35:393A.

    Google Scholar 

  40. Becker R, Spencer F, You F: How important is unfractionated heparin as adjunctive pharmacotherapy with GP IIb/IIIa antagonists in acute coronary syndromes. J Am Coll Cardiol 2000, 35:393 A.

    Article  Google Scholar 

  41. Du XP, Plow EF, Frelinger AL, et al.: Ligands “activate” integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 1991, 65:409–416.

    Article  PubMed  CAS  Google Scholar 

  42. Adderley SR, Fitzgerald DJ: Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000, 275:5760–5766.

    Article  PubMed  CAS  Google Scholar 

  43. Buckley CD, Pilling D, Henriquez NV, et al.: RGD peptides induce apoptosis by direct caspase-3 activation. Nature 1999, 397:534–539.

    Article  PubMed  CAS  Google Scholar 

  44. Topol EJ, Easton JD, Amarenco P, et al.: Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J 2000, 139:927–933.

    Article  PubMed  CAS  Google Scholar 

  45. Akkerhuis M, van der Zwaan C, Wilcox R, et al.: Troponin-I identifies patients with unstable coronary artery disease who benefit from long-term oral glycoprotein IIb/IIIa inhibition. Circulation 1999, 100:I-292.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Derek P. Chew MBBS & Deepak L. Bhatt MD

Authors
  1. Derek P. Chew MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deepak L. Bhatt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chew, D.P., Bhatt, D.L. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 3, 63–71 (2001). https://doi.org/10.1007/s11886-001-0012-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-001-0012-2

Keywords

Search

Navigation